Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 4
2003 1
2005 4
2006 6
2007 6
2008 7
2009 9
2010 11
2011 10
2012 9
2013 4
2014 10
2015 9
2016 9
2017 4
2018 6
2019 5
2020 7
2021 7
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial.
Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K. Nishikawa T, et al. Among authors: mori m. J Clin Oncol. 2023 May 20;41(15):2789-2799. doi: 10.1200/JCO.22.02558. Epub 2023 Mar 28. J Clin Oncol. 2023. PMID: 36977309 Free PMC article.
25th anniversary of oral diseases.
Johnson NW, Warnakulasuriya S, Greenspan J, Mori M, Baum B. Johnson NW, et al. Among authors: mori m. Oral Dis. 2021 Sep;27(6):1339-1342. doi: 10.1111/odi.13709. Epub 2020 Nov 30. Oral Dis. 2021. PMID: 33140899 No abstract available.
Does ionizing radiation influence Alzheimer's disease risk?
Begum N, Wang B, Mori M, Vares G. Begum N, et al. Among authors: mori m. J Radiat Res. 2012 Nov 1;53(6):815-22. doi: 10.1093/jrr/rrs036. Epub 2012 Aug 7. J Radiat Res. 2012. PMID: 22872779 Free PMC article. Review.
Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.
Tamai H, Ikeda K, Miyamoto T, Taguchi H, Kuo CF, Shin K, Hirata S, Okano Y, Sato S, Yasuoka H, Kuwana M, Ishii T, Kameda H, Kojima T, Taninaga T, Mori M, Miyagishi H, Sato Y, Tsai WC, Takeuchi T, Kaneko Y; MIRACLE study collaborators. Tamai H, et al. Among authors: mori m. Lancet Rheumatol. 2023 Apr;5(4):e215-e224. doi: 10.1016/S2665-9913(23)00070-X. Lancet Rheumatol. 2023. PMID: 38251524 Clinical Trial.
Validity of the COmprehensive Score for financial Toxicity (COST) in patients with gynecologic cancer.
Kajimoto Y, Shibutani T, Nagao S, Yamaguchi S, Suzuki S, Mori M, Tsubouchi H, Nakao K, Azuma A, Koyanagi T, Kohara I, Tamaki S, Yabuki M, Teng L, Honda K, Igarashi A. Kajimoto Y, et al. Among authors: mori m. Int J Gynecol Cancer. 2022 Apr 20:ijgc-2022-003410. doi: 10.1136/ijgc-2022-003410. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 35444012
125 results